Cargando…

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer

OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaka, Saki, Kondo, Eiji, Kawai, Yosuke, Okamoto, Kota, Kishigami, Yasuyuki, Yamawaki, Takaharu, Nagao, Kenji, Hirata, Toru, Suzuki, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482586/
https://www.ncbi.nlm.nih.gov/pubmed/37170726
http://dx.doi.org/10.3802/jgo.2023.34.e60
_version_ 1785102203117109248
author Kotaka, Saki
Kondo, Eiji
Kawai, Yosuke
Okamoto, Kota
Kishigami, Yasuyuki
Yamawaki, Takaharu
Nagao, Kenji
Hirata, Toru
Suzuki, Shiro
author_facet Kotaka, Saki
Kondo, Eiji
Kawai, Yosuke
Okamoto, Kota
Kishigami, Yasuyuki
Yamawaki, Takaharu
Nagao, Kenji
Hirata, Toru
Suzuki, Shiro
author_sort Kotaka, Saki
collection PubMed
description OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. METHODS: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. RESULTS: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. CONCLUSION: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies.
format Online
Article
Text
id pubmed-10482586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-104825862023-09-08 Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer Kotaka, Saki Kondo, Eiji Kawai, Yosuke Okamoto, Kota Kishigami, Yasuyuki Yamawaki, Takaharu Nagao, Kenji Hirata, Toru Suzuki, Shiro J Gynecol Oncol Original Article OBJECTIVE: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. METHODS: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. RESULTS: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. CONCLUSION: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2023-04-28 /pmc/articles/PMC10482586/ /pubmed/37170726 http://dx.doi.org/10.3802/jgo.2023.34.e60 Text en © 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kotaka, Saki
Kondo, Eiji
Kawai, Yosuke
Okamoto, Kota
Kishigami, Yasuyuki
Yamawaki, Takaharu
Nagao, Kenji
Hirata, Toru
Suzuki, Shiro
Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title_full Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title_fullStr Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title_full_unstemmed Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title_short Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
title_sort real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482586/
https://www.ncbi.nlm.nih.gov/pubmed/37170726
http://dx.doi.org/10.3802/jgo.2023.34.e60
work_keys_str_mv AT kotakasaki realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT kondoeiji realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT kawaiyosuke realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT okamotokota realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT kishigamiyasuyuki realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT yamawakitakaharu realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT nagaokenji realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT hiratatoru realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer
AT suzukishiro realworldefficacyandsafetyofbevacizumabsinglemaintenancetherapyfollowingplatinumpaclitaxelchemotherapyplusbevacizumabinpatientswithadvancedcervicalcancer